Expert Interview
Potential for Protalix' (PLX) OPRX-106 in Ulcerative Colitis, and What to Expect from Phase 2 Data
Ticker(s): PLXA gastroenterologist or other specialist with experience treating patients with ulcerative colitis. He or she must be familiar with the Phase 1 and Phase 2 data for OPRX-106.
Please describe your background treating ulcerative colitis and familiarity with OPRX-106.
Added By: pjloriaWhat current treatment options are used in your office, and how effective and safe are they?
Added By: pjloriaHow do these treatment options compare to OPRX-106 in safety and efficacy?
Added By: pjloriaOPRX-106 is a plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc). Can you talk about your view of this compound and its potential in ulcerative colitis?
Added By: pjloriaWhat are your thoughts on the Phase 1 data? Is 15 a large enough population for the study?
Added By: pjloriaThe Phase 2 study recently initiated enrollment, and data is expected in the second half of 2017. Can you give us your thoughts on the design and your expectations for the study?
Added By: pjloriaBased on your current knowledge, what is the potential for OPRX-106 in the ulcerative colitis market? What are the chances the drug is approved?
Added By: pjloriaAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Phase 2 Data due in Q1 2018 for Protalix' (PLX) OPRX-106 in Ulcerative Colitis PLX Occurred On: Jan 02, 2018
- Enrollment Expected to Commence Soon in Phase 2 Trial Evaluating Protalix' (PLX) OPRX-106 in Ulcerative Colitis PLX Occurred On: Nov 30, 2016
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
